Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Amisulpride · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Amisulpride | DRUG | - |
Inclusion Criteria: Pre-Inclusion Criteria on D-3: * In-patients * From 18 to 65 years old * Able to comply with the protocol * Having given their written informed consent (with a legal representative or a person of trust) * Current diagnosis of bipolar I disorder according to DSM IV TR (APA 2000)...
Top 10 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 4 | PHASE3 | Xanomeline and trospium chloride, Xanomeline/Trospium Chloride |
| AbbVie, Inc. | ABBV | 3 | PHASE3 | Cariprazine, ABBV-932, Icalcaprant |
| Xenon Pharmaceuticals Inc. | XENE | 2 | PHASE3 | Azetukalner |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Rapport Therapeutics, Inc. | RAPP | 1 | PHASE2 | RAP-219 |
| Neurocrine Biosciences, Inc. | NBIX | 1 | PHASE2 | NBI-1117568 |
| Alto Neuroscience, Inc. | ANRO | 1 | PHASE2 | ALTO-100 |
| LB Pharmaceuticals, Inc. | LBRX | 1 | PHASE2 | LB-102 |
| BioXcel Therapeutics, Inc. | BTAI | 1 | PHASE1 | BXCL501 |
| Alzamend Neuro, Inc. | ALZN | 1 | PHASE1 | AL001 |
Amisulpride is being studied for use in bipolar disorder, specifically in patients with bipolar I disorder. It has been evaluated in a Phase 2 clinical trial called SOLMANIA, which compared valproate plus amisulpride against valproate plus haloperidol in adults with bipolar I disorder.
Amisulpride acts as an antagonist at several serotonin receptors: HTR1A, HTR1B, HTR1F, HTR2B, HTR3A, and HTR4. Antagonist activity means the drug blocks signaling through these receptors. This receptor profile places amisulpride among small molecule compounds that modulate serotonin receptor activity.
Amisulpride is developed by Sanofi, which trades under the ticker SNY. Sanofi is the company associated with the clinical development of the drug in the bipolar disorder program.
Amisulpride is in Phase 2 development for bipolar disorder. It is an investigational small molecule and is not described as approved for this indication. The Phase 2 program includes one completed trial, and no trials are currently active.
Amisulpride has been studied in the Phase 2 SOLMANIA trial, registered as NCT00126009. The trial compared valproate plus amisulpride with valproate plus haloperidol in bipolar I patients, enrolled 120 participants, was randomized, and was conducted in Czechia, France, Poland, Slovakia, and Spain. It is now completed.